Clinical significance of serum soluble B7-H3 in patients with osteosarcoma

Cancer Cell International

Fu-biao Kang¹  Guo-chuan Zhang²  Ling Wang²  Ming-fang Xie²  Ying-ze Zhang³  Juan Wang⁴ 

[1] Department of Liver Diseases, Bethune International Peace Hospital;Department of Orthopedic Oncology, The Third Hospital of Hebei Medical University;Department of Orthopedic Research Center, The Third Hospital of Hebei Medical University;Department of Orthopedic Surgery, The Third Hospital of Hebei Medical University;

关键词: Osteosarcoma;    B7-H3;    Tumor biomarker;    Bone tumor;    Prognosis;   

DOI  :  10.1186/s12935-018-0614-z

来源: DOAJ

【 摘 要 】

Abstract Background Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma (OS) are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a tool for differential diagnosis of OS patients. Methods Peripheral blood samples from healthy controls, benign bone tumors, and OS patients were collected. Levels of sB7-H3 in serum samples were measured by enzyme-linked immunosorbent assays. The correlation between OS-derived sB7-H3 and clinical features was analyzed, and prognostic significance of the sB7-H3 concentrations and tumor expressions of the biomarkers was then evaluated. Results sB7-H3 concentrations were significantly increased in patients with OS than in osteochondroma patients, bone fibrous dysplasia patients and healthy people (p < 0.05, respectively). Using 60.94 ng/mL as a cutoff value, the sensitivity and specificity of sB7-H3 was to differentiate between OS patients and other bone benign tumor patients were 75.7% and 83.8%, respectively. In addition, upregulated serum sB7-H3 in patients with OS associated with tumor differentiation, tumor stage, and metastasis status (p < 0.05, respectively). The area under the curve value for sB7-H3 (0.868) was markedly higher than those for ALP (0.713) and CA125 (0.789) for differentiating between OS patients and other begin bone tumor patients. Conclusions We demonstrated that enhanced sB7-H3 levels correlated with the clinical characteristics of OS patients, and B7-H3 might be a potential biomarker and associated with the pathogenesis of OS.

【 授权许可】

Unknown